How to buy Bioventus stock | $17.78

Bioventus Inc is a diagnostics & research business based in the US. Bioventus shares (BVS) are listed on the NASDAQ and all prices are listed in US Dollars. Bioventus employs 900 staff and has a trailing 12-month revenue of around 0.00.

Bioventus stock price (NASDAQ: BVS)

Use our graph to track the performance of BVS stocks over time.

Bioventus shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$17.78
52-week range	$10.74 - $19.94
50-day moving average	$17.20
200-day moving average	$15.64
Wall St. target price	$20.33
PE ratio	38.2812
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.45

Buy Bioventus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Bioventus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Bioventus Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bioventus price performance over time

Historical closes compared with the close of $17.78 from 2021-05-28

1 week (2021-07-21)	N/A
1 month (2021-07-01)	3.31%
3 months (2021-04-30)	23.47%
6 months (2021-01-28)	N/A

1 year (2020-07-28)	N/A
2 years (2019-07-28)	N/A
3 years (2018-07-28)	N/A
5 years (2016-07-28)	N/A

Is Bioventus under- or over-valued?

Valuing Bioventus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bioventus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bioventus's P/E ratio

Bioventus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, Bioventus shares trade at around 38x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Bioventus's P/E ratio is best considered in relation to those of others within the diagnostics & research industry or those of similar companies.

• Johnson-and-Johnson (JNJ.US): 25.88
• Merck-and-CoInc (MRK.US): 27.78

Bioventus's PEG ratio

Bioventus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4792. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bioventus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Bioventus's PEG ratio in relation to those of similar companies.

• Bristol-Myers Squibb Company (BMY.US): 31.93
• Johnson-and-Johnson (JNJ.US): 1.90
• Merck-and-CoInc (MRK.US): 1.64

Bioventus's EBITDA

Bioventus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $55.1 million.

The EBITDA is a measure of a Bioventus's overall financial performance and is widely used to measure a its profitability.

To put Bioventus's EBITDA into context you can compare it against that of similar companies.

• Bristol-Myers Squibb Company (BMY.US): USD$18.3 billion
• Johnson-and-Johnson (JNJ.US): USD$30.6 billion
• Merck-and-CoInc (MRK.US): USD$18.6 billion

Bioventus financials

Revenue TTM	$324.3 million
Operating margin TTM	10.49%
Gross profit TTM	$233.5 million
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	9.38%
Book value	$3.47
Market capitalisation	$974.6 million

TTM: trailing 12 months

Shorting Bioventus shares

There are currently 377,456 Bioventus shares held short by investors – that's known as Bioventus's "short interest". This figure is 38.8% up from 271,935 last month.

There are a few different ways that this level of interest in shorting Bioventus shares can be evaluated.

Bioventus's "short interest ratio" (SIR)

Bioventus's "short interest ratio" (SIR) is the quantity of Bioventus shares currently shorted divided by the average quantity of Bioventus shares traded daily (recently around 154695.08196721). Bioventus's SIR currently stands at 2.44. In other words for every 100,000 Bioventus shares traded daily on the market, roughly 2440 shares are currently held short.

To gain some more context, you can compare Bioventus's short interest ratio against those of similar companies.

• Bristol-Myers Squibb Company (BMY.US): 2.1
• Johnson-and-Johnson (JNJ.US): 2.41
• Merck-and-CoInc (MRK.US): 1.85

However Bioventus's short interest can also be evaluated against the total number of Bioventus shares, or, against the total number of tradable Bioventus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bioventus's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Bioventus shares in existence, roughly 10 shares are currently held short) or 0.0475% of the tradable shares (for every 100,000 tradable Bioventus shares, roughly 48 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bioventus.

Find out more about how you can short Bioventus stock.

Bioventus share dividends

We're not expecting Bioventus to pay a dividend over the next 12 months.

You may also wish to consider:

• Bristol-Myers Squibb Company (BMY.US) (2.74% forward annual dividend yield)
• Johnson-and-Johnson (JNJ.US) (2.38% forward annual dividend yield)
• Merck-and-CoInc (MRK.US) (3.17% forward annual dividend yield)

Bioventus overview

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Frequently asked questions

What percentage of Bioventus is owned by insiders or institutions?
Currently 31.62% of Bioventus shares are held by insiders and 68.665% by institutions. How many people work for Bioventus?
Latest data suggests 900 work at Bioventus. When does the fiscal year end for Bioventus?
Bioventus's fiscal year ends in December. Where is Bioventus based?
Bioventus's address is: 4721 Emperor Boulevard, Durham, NC, United States, 27703